# | Title | Journal | Year | Citations |
---|
|
1 | A method for estimating the probability of adverse drug reactions | Clinical Pharmacology and Therapeutics | 1981 | 9,986 |
2 | Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework | Clinical Pharmacology and Therapeutics | 2001 | 5,548 |
3 | Nanoparticles in Medicine: Therapeutic Applications and Developments | Clinical Pharmacology and Therapeutics | 2008 | 2,198 |
4 | A physiological approach to hepatic drug clearance | Clinical Pharmacology and Therapeutics | 1975 | 1,746 |
5 | Pharmacogenomics Knowledge for Personalized Medicine | Clinical Pharmacology and Therapeutics | 2012 | 1,590 |
6 | Clinical biostatistics: LIV. The biostatistics of concordance | Clinical Pharmacology and Therapeutics | 1981 | 1,059 |
7 | Simultaneous modeling of pharmacokinetics and pharmacodynamics: Application to d‐tubocurarine | Clinical Pharmacology and Therapeutics | 1979 | 1,037 |
8 | CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network | Clinical Pharmacology and Therapeutics | 2011 | 930 |
9 | Pharmacogenetics: From Bench to Byte— An Update of Guidelines | Clinical Pharmacology and Therapeutics | 2011 | 890 |
10 | Identification of functionally variant MDR1 alleles among European Americans and African Americans | Clinical Pharmacology and Therapeutics | 2001 | 886 |
11 | Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man | Clinical Pharmacology and Therapeutics | 1971 | 875 |
12 | Monoclonal Antibody Pharmacokinetics and Pharmacodynamics | Clinical Pharmacology and Therapeutics | 2008 | 858 |
13 | Development of a Large-Scale De-Identified DNA Biobank to Enable Personalized Medicine | Clinical Pharmacology and Therapeutics | 2008 | 842 |
14 | Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update | Clinical Pharmacology and Therapeutics | 2013 | 810 |
15 | Case Definition and Phenotype Standardization in Drug-Induced Liver Injury | Clinical Pharmacology and Therapeutics | 2011 | 807 |
16 | Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance | Clinical Pharmacology and Therapeutics | 2004 | 789 |
17 | Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors | Clinical Pharmacology and Therapeutics | 2015 | 785 |
18 | Use of Pharmacogenetic and Clinical Factors to Predict the Therapeutic Dose of Warfarin | Clinical Pharmacology and Therapeutics | 2008 | 753 |
19 | Minimization: A new method of assigning patients to treatment and control groups | Clinical Pharmacology and Therapeutics | 1974 | 748 |
20 | Concentrations of Tramadol and O-desmethyltramadol Enantiomers in Different CYP2D6 Genotypes | Clinical Pharmacology and Therapeutics | 2007 | 746 |
21 | Drug interactions with lipid-lowering drugs: Mechanisms and clinical relevance | Clinical Pharmacology and Therapeutics | 2006 | 711 |
22 | Trends in Risks Associated With New Drug Development: Success Rates for Investigational Drugs | Clinical Pharmacology and Therapeutics | 2010 | 707 |
23 | Biodistribution of 89Zr-trastuzumab and PET Imaging of HER2-Positive Lesions in Patients With Metastatic Breast Cancer | Clinical Pharmacology and Therapeutics | 2010 | 704 |
24 | Changes in plasma protein binding have little clinical relevance | Clinical Pharmacology and Therapeutics | 2002 | 692 |
25 | Clinical pharmacology of buprenorphine: Ceiling effects at high doses | Clinical Pharmacology and Therapeutics | 1994 | 677 |
26 | Pharmacologic effects of CI‐581, a new dissociative anesthetic, in man | Clinical Pharmacology and Therapeutics | 1965 | 671 |
27 | I-SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy | Clinical Pharmacology and Therapeutics | 2009 | 670 |
28 | The CYP2D6 Activity Score: Translating Genotype Information into a Qualitative Measure of Phenotype | Clinical Pharmacology and Therapeutics | 2008 | 660 |
29 | Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine* | Clinical Pharmacology and Therapeutics | 1997 | 655 |
30 | Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects | Clinical Pharmacology and Therapeutics | 2001 | 639 |
31 | A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants | Clinical Pharmacology and Therapeutics | 2006 | 629 |
32 | Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450 2D6 Genotype and Codeine Therapy: 2014 Update | Clinical Pharmacology and Therapeutics | 2014 | 596 |
33 | Reduced β‐adrenoceptor sensitivity in the elderly | Clinical Pharmacology and Therapeutics | 1979 | 590 |
34 | Pharmacogenetics of acute azathioprine toxicity: Relationship to thiopurine methyltransferase genetic polymorphism | Clinical Pharmacology and Therapeutics | 1989 | 586 |
35 | Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus | Clinical Pharmacology and Therapeutics | 2003 | 586 |
36 | Learning versus confirming in clinical drug development* | Clinical Pharmacology and Therapeutics | 1997 | 576 |
37 | Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 Genotypes and Warfarin Dosing | Clinical Pharmacology and Therapeutics | 2011 | 576 |
38 | Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor | Clinical Pharmacology and Therapeutics | 2005 | 571 |
39 | ALDEN, an Algorithm for Assessment of Drug Causality in Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: Comparison With Case–Control Analysis | Clinical Pharmacology and Therapeutics | 2010 | 563 |
40 | Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism* | Clinical Pharmacology and Therapeutics | 1996 | 551 |
41 | Nicotine absorption and cardiovascular effects with smokeless tobacco use: Comparison with cigarettes and nicotine gum | Clinical Pharmacology and Therapeutics | 1988 | 550 |
42 | Fruit juices inhibit organic anion transporting polypeptide–mediated drug uptake to decrease the oral availability of fexofenadine | Clinical Pharmacology and Therapeutics | 2002 | 544 |
43 | The Challenge of Treating Biofilm-associated Bacterial Infections | Clinical Pharmacology and Therapeutics | 2007 | 538 |
44 | Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum)*1 | Clinical Pharmacology and Therapeutics | 1999 | 534 |
45 | Cyclosporine metabolism in human liver: Identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs | Clinical Pharmacology and Therapeutics | 1988 | 531 |
46 | Plasma propranolol levels in adults With observations in four children | Clinical Pharmacology and Therapeutics | 1970 | 525 |
47 | Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing | Clinical Pharmacology and Therapeutics | 2015 | 520 |
48 | St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4 | Clinical Pharmacology and Therapeutics | 2000 | 519 |
49 | Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing | Clinical Pharmacology and Therapeutics | 2011 | 514 |
50 | Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics‐Guided Warfarin Dosing: 2017 Update | Clinical Pharmacology and Therapeutics | 2017 | 509 |